Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2014, Article ID 913634, 5 pages
http://dx.doi.org/10.1155/2014/913634
Clinical Study

Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma

1Johns Hopkins Medicine, Division of Gastroenterology and Hepatology, Sibley Memorial Hospital, 5215 Loughboro Road, NW Suite No. 300, Washington, DC 20016, USA
2Georgetown University School of Medicine, Lombardi Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007, USA
3Georgetown University Hospital, Georgetown Transplant Institute, 3800 Reservoir Road NW, Washington, DC 20007, USA

Received 15 January 2014; Accepted 24 February 2014; Published 10 April 2014

Academic Editor: P. Burra

Copyright © 2014 Kirti Shetty et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. B. El-Serag, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Shetty, K. Timmins, C. Brensinger et al., “Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome,” Liver Transplantation, vol. 10, no. 7, pp. 911–918, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, “Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3129–3140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Roayaie, J. S. Frischer, S. H. Emre et al., “Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters,” Annals of Surgery, vol. 235, no. 4, pp. 533–539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. M. Olthoff, M. H. Rosove, C. R. Shackleton et al., “Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 221, no. 6, pp. 734–743, 1995, Erratum in Annals of Surgery, vol. 224, no. 5, article 686, 1996. View at Google Scholar · View at Scopus
  8. S. Saab, M. McTigue, R. S. Finn, and R. W. Busuttil, “Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy,” Experimental and Clinical Transplantation, vol. 8, no. 4, pp. 307–313, 2010. View at Google Scholar · View at Scopus
  9. C.-L. Teng, W.-L. Hwang, Y.-J. Chen, K.-H. Chang, and S.-B. Cheng, “Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study,” World Journal of Surgical Oncology, vol. 10, article 41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. F. Saidi, S. A. Shah, A. P. Rawson, S. Grossman, B. Piperdi, and A. Bozorgzadeh, “Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience,” Transplantation Proceedings, vol. 42, no. 10, pp. 4582–4584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Gomez-Martin, J. Bustamante, J. F. Castroagudin et al., “Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation,” Liver Transplantation, vol. 18, no. 1, pp. 45–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Vitale, G. Lombardi, R. Ramirez Morales, and U. Cillo, “Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma,” Digestive and Liver Disease, vol. 44, no. 5, pp. 361–362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Weinmann, I. M. Niederle, S. Koch et al., “Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation,” Digestive and Liver Disease, vol. 44, no. 5, pp. 432–437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Waidmann, W.-P. Hofmann, S. Zeuzem, and J. Trojan, “MTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation,” Journal of Hepatology, vol. 54, no. 2, pp. 396–398, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. J. Schlitt and A. A. Schnitzbauer, “Hepatocellular carcinoma: agents and concepts for preventing recurrence after curative treatment,” Liver Transplantation, vol. 17, supplement 3, pp. S10–S12, 2011. View at Google Scholar · View at Scopus
  16. H. A. Edmondson and P. E. Steiner, “Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies,” Cancer, vol. 7, no. 3, pp. 462–503, 1954. View at Google Scholar